Key result
Baseline insulin resistance was associated with an approximately 60% higher risk of developing incident atrial fibrillation compared with HOMA-IR <1.4.
Why the study?
Does baseline insulin resistance increase the risk of incident atrial fibrillation in individuals free of diabetes and AF?
Does baseline insulin resistance increase the risk of incident atrial fibrillation in individuals free of diabetes and AF?
Answers are grounded in this paper and cite their sources.
Baseline insulin resistance, even at levels below traditional thresholds, is an independent predictor of incident atrial fibrillation in a South Korean population.
Atrial fibrillation (AF) is common and confers high morbidity and mortality, despite recent progress in stroke prevention and interventional management of the arrhythmia.1 In order to decrease the burden and improve outcomes, a focus has been placed on risk factors responsible for AF development and recurrence. The Atherosclerosis Risk in Communities Study (ARIC) revealed that suboptimal risk factor control accounted for over 50% of AF incidence among middle-aged individuals.2 Metabolic syndrome and type 2 diabetes, both highly prevalent and associated with insulin resistance, have been independently associated with AF.3,4 This has raised interest in insulin resistance as a potentially modifiable risk factor for AF. However, current evidence is conflicting, and it remains unresolved whether insulin resistance can contribute to AF development alone, or only in conjunction with other factors (i.e. in the metabolic syndrome/diabetes). In the present issue of the journal, Lee et al.5 provide a novel insight into the contribution of baseline insulin resistance, as measured by the homeostatic model of insulin resistance (HOMA-IR), to the long-term risk of incident AF. This report presents a large community-based longitudinal study, involving 8175 participants from the urban (Ansan) and rural (Ansung) areas in South Korea. The participants, free of diabetes and AF at baseline, were enrolled between 2001 and 2003. The development of incident AF was determined by electrocardiography at follow-up visits performed every 2 years until 2014. Over the median follow-up of 12.3 years, 136 individuals developed AF (incidence rate 1.89/1000 patient-years). HOMA-IR above the study population median (≥1.4) conferred and approximately 60% higher risk of developing AF compared with HOMA-IR below the population median (<1.4). This association remained significant following adjustments for sociodemographic parameters and risk factors, such as hypertension, vascular disease, heart failure, chronic pulmonary disorders, thyroid dysfunction and adiposity. The significance of insulin resistance for AF development was similar in subgroups dichotomised on the basis of sex, age (cut-off 50 years), obesity (cut-off body mass index 25 kg/m2), abdominal obesity, hypertension, smoking and alcohol intake. The mediation analyses demonstrated that the risk of AF in individuals with general or abdominal obesity was largely explained by the impact of insulin resistance. Of note, the association with AF steeply increased between HOMA-IR levels 1 and 2, followed by a less pronounced increase up to the plateau level of approximately 2.5. These levels are significantly below the HOMA-IR ‘threshold’, commonly used to denote the presence of insulin resistance (i.e. HOMA-IR >2.5) in most studies of Caucasian patients.6,7 Interestingly, there was no further increase in the risk of AF above the plateau HOMA-IR 2.5. The strength of the present study is conferred by its large sample size, long duration and meticulous documentation of AF during the follow-up. Indeed, the difference in the event rate (i.e. AF occurrence) between patients with high and low HOMA-IR was small (only 1.1%). Probably, detecting such a small difference was only possible with a large sample size and long-term follow-up. However, a long study duration is also a limitation, given that new factors could have influenced the development of AF independent of baseline insulin resistance. In that respect, the authors demonstrated that the impact of baseline insulin resistance was not attenuated by the intercurrent development of type 2 diabetes (entered into the analysis as a time-dependent covariate), which may be the most important confounder of the association between insulin resistance and AF. However, it was not possible to assess other intercurrent confounders (e.g. new-onset arterial hypertension, left ventricular hypertrophy, acute coronary syndromes, incident heart failure, etc.), which could have driven AF development beyond the impact of baseline insulin resistance. Two findings of the present study are of particular interest. Firstly, there was a steep increase in the risk of incident AF associated with relatively low HOMA-IR (between 1 and 2), while no further increase occurred above HOMA-IR 2.5, the value which is equal to, or similar to, the ‘threshold’ for insulin resistance in many western populations.6,8 This observation may be attributed to the competing risk of unrecognised cardiometabolic confounders, which could cluster in individuals with greater insulin resistance, thus attenuating the association with AF. A similar ‘plateau effect’ was observed for the association between insulin resistance and incident heart failure.7 Secondly, the present study suggested that insulin resistance is an independent predictor of subsequent AF, which has not been demonstrated in previous large cohort studies.9,10 One explanation is that this was the largest study and, therefore, most capable of detecting a small effect size, which could have gone unnoticed in previous research. It is also possible that ethnic differences influenced the risk of incident AF in patients with insulin resistance. Unlike previous studies of mixed (mostly Caucasian) patient groups, the present study included only a South Asian population. It appears that South Asians have an increased propensity for insulin resistance and central adiposity, which occur at a younger age and at lower body mass index compared with other ethnic groups.11 In addition to a different pattern of adiposity, there seems to be an increased prevalence of adipose tissue dysfunction in South Asians, which may confer a higher risk of cardiometabolic complications.11 Therefore, insulin resistance detected at lower values of HOMA-IR in the present study may be an early sign, and a more sensitive indicator of cardiometabolic risk in South Asians compared with western populations. This is supported by the mediation analysis suggesting that insulin resistance was largely responsible for AF in the setting of central and generalised obesity in the current study.12 Despite the large sample size and robust analyses, the study by Lee et al.5 has not resolved the issue of whether insulin resistance independently contributes to incident AF. From the clinical standpoint, this matter is less relevant because insulin resistance is rarely an isolated condition. Indeed, in western populations it is usually a component of the metabolic syndrome and a precursor of type 2 diabetes, while in the South Asian population it is usually accompanied by abdominal obesity, even in the absence of other features of the metabolic syndrome. Even more challenging is the degree of insulin resistance (HOMA-IR) that should raise the awareness of clinicians about the attending risk. Apparently, the threshold of insulin resistance relevant for AF occurrence differs among populations and needs to be investigated further. Also, the impact of interventions aimed to improve insulin resistance for the prevention of AF remain unknown.13,14 However, these observations do not diminish the significance of cardiometabolic abnormalities, including insulin resistance, for cardiovascular health.15 In particular, patients with AF deserve careful assessment, given the high prevalence and increased risk of adverse outcomes in the presence of the metabolic syndrome.16 In addition, the present study extends current knowledge and promotes further research into potentially modifiable risk factors for common cardiovascular disorders, including AF.
No takes yet. Share an insight, caveat, or question.
Polovina et al. (2020) conducted an editorial in Atrial fibrillation (n=8,175). Baseline insulin resistance (HOMA-IR ≥1.4) vs. HOMA-IR <1.4 was evaluated on Incident atrial fibrillation (approx 60% higher risk). Baseline insulin resistance was associated with an approximately 60% higher risk of developing incident atrial fibrillation compared with HOMA-IR <1.4.
Synapse has enriched 10 related papers. Consider them for comparative context: